Moderna Inc. (MRNA)
Moderna Inc. (MRNA) Stock Price, Analysis & Data
| Bid | 59.39 |
| Market Cap | 25.28B |
| Revenue (ttm) | 2.23B |
| Net Income (ttm) | -3.15B |
| Beta | 0.90 |
| EPS (ttm) | -7.98 |
| PE Ratio (ttm) | n/a |
| Forward PE | -12.93 |
| P/B (ttm) | 3.74 |
| P/S (ttm) | 11.35 |
| Earnings Date | Nov 5, 2026 |
| Ask | 66.05 |
| Volume | 4,690,165 |
| Avg. Volume (20D) | 6,916,770 |
| Open | 62.71 |
| Previous Close | 63.65 |
| Day's Range | 60.82 - 63.78 |
| 52-Week Range | 22.28 - 85.60 |
| Analyst | Hold |
| Price Target | 45 (-28.93%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zi...
Financial Performance
In 2025, Moderna's revenue was 1.92B, a decrease of -39.92% compared to the previous year's 3.2B. Earnings were -2.82B, a decrease of -20.75%.
Financial StatementsAnalyst Forecast
According to 19 analyst ratings, the average rating for MRNA stock is "Hold". The 12-month stock price forecast is 45, which is downside of 28.93% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
